BMS cleared to wrap up Medarex buy; Stada CFO leaves 'by mutual consent';

> Bristol-Myers Squibb said a regulatory review period for its acquisition of Medarex has expired, allowing the $2.1 billion deal to go forward. Report

> Danish drugmaker H. Lundbeck reported a slightly smaller-than-expected rise in operating profits and stuck to its full-year 2009 earnings and revenue guidance. Report

> German generics maker Stada said CFO Wolfgang Jeblonski would leave immediately "by mutual consent" as the company reported a 20 percent drop in first-half adjusted net income. Report

> Endo Pharmaceuticals said Chief Operating Officer Nancy Wysenski will resign Sept. 1 to deal with family matters. Report

> Celesio, Europe's largest drug wholesaler, said second-quarter profit rose 1.1 percent to $93.4 million due to lower taxes. Report

> Teva Pharmaceutical Industries says it has launched its version of the Sanofi-Aventis colon-cancer treatment Eloxatin. Report

> India's Orchid Pharmaceuticals got the FDA nod for its version of Imitrex, the GlaxoSmithKline migraine drug. Report

Biotech News

> NuPathe announced positive results from a key late-stage study of Zelrix, a transdermal patch designed for the treatment of acute migraine. Report

> Pacific Biosciences is on a roll. The 2009 Fierce 15 winner, which is developing genetic sequencing tech, has raised $68 million in financing with the help of several new investors. Report

> Forest Laboratories has inked a collaboration agreement with AstraZeneca giving AZ the right to co-develop and market Forest's anti-infective drug ceftaroline outside the United States, Canada and Japan. Report

> Most biotech and pharma companies struggle to enroll patients in clinical trials, but not Seattle Genetics. The company, which is testing an antibody to treat Hodgkin's disease, is enrolling trials of the drug so quickly that it's six months ahead of schedule, according to a piece in Xconomy. Report

Vaccines News

> Dynavax Technologies has been talking with regulators in Europe about the potential for developing Heplisav, an experimental hepatitis B vaccine, for people over 40 who aren't responding to currently marketed therapies. Report

> Dr. Tadataka ‘Tachi' Yamada, president of the Gates Foundation's Global Health Program, has some tough words for affluent countries that use their money to buy their way to the front of the line for pandemic vaccines. Report

> The editorial board at the San Jose Mercury-News did the math on vaccinating every American versus the likely impact of a tsunami of new flu cases and came down hard on the side of ramping up vaccine production. Report

> Bracing for an expected 'second wave' of swine flu cases once schools reopen in the fall, British officials are hammering out plans for a nationwide vaccination campaign. Report

And Finally... After a new study provided tantalizing evidence that aspirin might increase survival chances for colorectal cancer patients, experts warn that the drug also has its risks. Report

Suggested Articles

Despite having lost some of its novelty, AZ's Brilinta is touting bleeding data over aspirin that could be a big break in acute coronary syndrome.

More than a year after J&J and Bayer pulled the plug on Xarelto in patients after a rare valve replacement, the pair are still seeking answers.

Having already whiffed on one crucial heart failure trial, Novartis is focusing on "profound" data from its Entresto studies in hopes for another go.